Inhibition of CYP2B6 by medicinal plant extracts : implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings

Simple item page
dc.contributor.authorThomford, Nicholas E.en_ZA
dc.contributor.authorAwortwe, Charlesen_ZA
dc.contributor.authorDzobo, Kevinen_ZA
dc.contributor.authorAdu, Faustinaen_ZA
dc.contributor.authorChopera, Denisen_ZA
dc.contributor.authorWonkam, Ambroiseen_ZA
dc.contributor.authorSkelton, Michelleen_ZA
dc.contributor.authorBlackhurst, Deeen_ZA
dc.contributor.authorDandara, Colleten_ZA
dc.date.accessioned2017-07-19T07:36:06Z
dc.date.available2017-07-19T07:36:06Z
dc.date.issued2016-02-16
dc.descriptionCITATION: Thomford, N. E. et al. 2016. Inhibition of CYP2B6 by medicinal plant extracts : implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings. Molecules, 21(2):211, doi:10.3390/molecules21020211.
dc.descriptionThe original publication is available at http://www.mdpi.com/journal/molecules
dc.description.abstractHighly active antiretroviral therapy (HAART) has greatly improved health parameters of HIV infected individuals. However, there are several challenges associated with the chronic nature of HAART administration. For populations in health transition, dual use of medicinal plant extracts and conventional medicine poses a significant challenge. There is need to evaluate interactions between commonly used medicinal plant extracts and antiretroviral drugs used against HIV/AIDS. Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts. The purpose of this study was to evaluate the effects of extracts of selected commonly used medicinal plants on CYP2B6 enzyme activity. Recombinant human CYP2B6 was used to evaluate inhibition, allowing the assessment of herb-drug interactions (HDI) of medicinal plants Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia, Boerhavia diffusa and Newbouldia laevis. The potential of these medicinal extracts to cause HDI was ranked accordingly for reversible inhibition and also classified as potential time-dependent inhibitor (TDI) candidates. The most potent inhibitor for CYP2B6 was Hyptis suaveolens extract (IC50 = 19.09 ± 1.16 µg/mL), followed by Myrothamnus flabellifolius extract (IC50 = 23.66 ± 4.86 µg/mL), Launaea taraxacifolia extract (IC50 = 33.87 ± 1.54 µg/mL), and Boerhavia diffusa extract (IC50 = 34.93 ± 1.06 µg/mL). Newbouldia laevis extract, however, exhibited weak inhibitory effects (IC50 = 100 ± 8.71 µg/mL) on CYP2B6. Launaea taraxacifolia exhibited a TDI (3.17) effect on CYP2B6 and showed a high concentration of known CYP450 inhibitory phenolic compounds, chlorogenic acid and caffeic acid. The implication for these observations is that drugs that are metabolized by CYP2B6 when co-administered with these herbal medicines and when adequate amounts of the extracts reach the liver, there is a high likelihood of standard doses affecting drug plasma concentrations which could lead to toxicity.en_ZA
dc.description.urihttp://www.mdpi.com/1420-3049/21/2/211
dc.description.versionPublisher's version
dc.format.extent15 pages
dc.identifier.citationThomford, N. E. et al. 2016. Inhibition of CYP2B6 by medicinal plant extracts : implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings. Molecules, 21(2):211, doi:10.3390/molecules21020211.
dc.identifier.issn1420-3049 (online)
dc.identifier.otherdoi:10.3390/molecules21020211
dc.identifier.urihttp://hdl.handle.net/10019.1/101992
dc.language.isoen_ZAen_ZA
dc.publisherMDPI
dc.rights.holderAuthors retain copyright
dc.subjectAntiretroviral therapyen_ZA
dc.subjectMedicinal plantsen_ZA
dc.subjectAIDS (Disease)en_ZA
dc.subjectHIV infectionsen_ZA
dc.subjectEnzymesen_ZA
dc.subjectCytochrome P-450en_ZA
dc.titleInhibition of CYP2B6 by medicinal plant extracts : implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settingsen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thomford_inhibition_2016.pdf
Size:
2.24 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Clinical Pharmacology)